10-Q: H.B. Fuller Q2 2026 Earnings and Strategic Acquisition

H.B. Fuller reports strong Q2 2026 revenue growth and announces a definitive agreement to acquire Advanced Medical Solutions Group plc.

Summary

• Net revenue for Q2 2026 was $950.3 million, a 5.8% increase compared to Q2 2025.
• Net income attributable to H.B. Fuller rose to $67.8 million in Q2 2026 from $41.8 million in Q2 2025.
• Diluted earnings per share (EPS) for Q2 2026 was $1.23, compared to $0.76 in the prior year period.
• Adjusted EBITDA for Q2 2026 increased 9.3% to $181.0 million.
• The company announced a recommended cash offer to acquire Advanced Medical Solutions Group plc for approximately 659 million British pounds.
• The company secured up to $3.0 billion in bridge credit facilities to fund the pending acquisition.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report characterized by solid margin expansion and a transformative, growth-oriented acquisition, despite minor volume headwinds.

Positives

• Revenue growth of 5.8% in Q2 2026 driven by pricing and currency effects.
• Gross profit margin expanded by 170 basis points to 33.6% due to pricing actions and restructuring benefits.
• Significant year-over-year increase in net income and diluted EPS.
• Strong free cash flow generation of $12.8 million for the first six months of 2026 compared to a use of cash of $6.7 million in the prior year period.
• Successful execution of restructuring plans contributing to margin improvement.

Negatives

• Sales volume decreased by 0.4% in Q2 2026.
• SG&A expenses increased as a percentage of net revenue due to higher compensation costs.
• Foreign currency losses impacted Adjusted EBITDA.
• Increased debt levels compared to the prior year period.

Risks

• Exposure to foreign currency exchange rate fluctuations affecting earnings and net investment.
• Potential for adverse outcomes in ongoing asbestos-related litigation and environmental investigations.
• Integration risks associated with the pending acquisition of Advanced Medical Solutions Group plc.
• Reliance on third-party supplier finance programs.
• Potential for increased interest expense if debt levels remain high or interest rates rise.

Future Outlook

The company expects to close the acquisition of Advanced Medical Solutions Group plc by the end of the calendar year, subject to regulatory and shareholder approvals. Restructuring actions related to global footprint optimization are expected to continue through fiscal year 2028.

Management Comments

• Management emphasizes the acquisition of Advanced Medical Solutions Group plc as a strategic move to shift the portfolio toward higher-growth, higher-margin markets.
• Management confirms that disclosure controls and procedures were effective as of May 30, 2026.

Industry Context

StockSavvy.ai notes that H.B. Fuller is aggressively pursuing a portfolio shift toward medical adhesives, a high-margin segment, while simultaneously optimizing its global manufacturing footprint to combat inflationary pressures and volume stagnation in its core industrial adhesive segments.

Comparison to Industry Standards

• The company's focus on medical adhesives aligns with industry trends toward high-value specialty chemical applications.
• The use of bridge financing for large acquisitions is consistent with standard practices for large-cap industrial companies.
• The company's gross margin expansion is a positive indicator of pricing power relative to peers in the specialty chemicals sector.

Legal Proceedings

• Ongoing asbestos-related litigation and environmental remediation activities.
• Settlement reached in Rouse et al. v. H.B. Fuller Company et al. for up to $75 million, with a $34.8 million accrual recorded.

Stakeholder Impact

• Shareholders may benefit from the strategic shift toward higher-margin medical adhesives.
• Creditors are impacted by the significant increase in debt capacity utilized for the pending acquisition.

Next Steps

• Complete the acquisition of Advanced Medical Solutions Group plc by the end of 2026.
• Continue implementation of global footprint optimization restructuring actions through 2028.
• Continue share repurchases under the 2022 authorization.

Key Dates

Recommendation

The combination of strong earnings growth, margin expansion, and a clear strategic pivot toward a high-growth medical adhesive market makes the stock attractive for long-term investors.

Keywords

H.B. Fuller, Adhesives, Specialty Chemicals, Earnings Report, Mergers and Acquisitions, Advanced Medical Solutions, Financial Results